Such compounds may not be effective against colorectal cancers in which the Wnt/β-catenin pathway is deregulated by mutations in downstream components APC and CTNNB1. Recent studies suggest that such targeting of downstream signaling could provide therapeutic advantages over targeting upstream signaling components [30, 31]. The gene discussed is CTNNB1; the disease is colorectal cancer.